Pharmaceutical giants have recently shown new enthusiasm for mental-health treatments with vast but unrealized promise.

Shares of Intra-Cellular Therapies are surging 35% in premarket trading Monday after Johnson & Johnson said it will acquire ...

Intra-Cellular has had success selling Caplyta, a brain-rebalancing drug that's approved to treat schizophrenia and bipolar ...

NDA submitted to U.S. FDA for CAPLYTA® as adjunctive treatment for major depressive disorder; if approved, CAPLYTA® has ...

SINGAPORE (The Straits Times/ANN): Ketamine, the controlled drug best known as a horse tranquilliser or party supplement, has ...

Cellular’s neuropsychiatric assets is Caplyta, a pill approved for schizophrenia and bipolar depression and proposed for ...

Johnson & Johnson JNJ-0.50%decrease ... a pill that treats bipolar depression and schizophrenia. Analysts predict the drug’s sales could reach $4 billion a year by 2030 if regulators approve ...

depression. Back in 2018, Johnson opened up about his struggles with mental health, showing fans that even the “big guy” isn’t invincible. It all started with a raw confession. Johnson ...

S&P Global Ratings placed Johnson & Johnson on CreditWatch with negative implications, citing its nearly $15 billion deal to acquire mental-illness drug developer Intra-Cellular Therapies.

Johnson & Johnson, already a big player in ... Two years later, its label expanded to include bipolar depression. Caplyta is a small molecule formulated as a capsule taken once daily.

Johnson & Johnson (J&J) has announced it will acquire Intra-Cellular Therapies, a company specialising in central nervous ...